World Journal of Gastrointestinal Pharmacology and Therapeutics
Cure8 research brief
Why This Matters
Patients who lose response to standard upadacitinib dosing may have a practical option—dose re‑escalation—that could improve symptoms and reduce steroid needs according to a small retrospective cohort summarized here.
Who Should Pay Attention
Adults with IBD (Crohn’s disease or ulcerative colitis) who are on or considering upadacitinib, treating gastroenterologists, and researchers studying JAK inhibitors or treatment optimization strategies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is an editorial summarizing and commenting on a small retrospective cohort; it is not a randomized trial. The available evidence described is preliminary and observational, so it can suggest hypotheses and pragmatic strategies but cannot establish comparative effectiveness or long‑term safety.
If someone is experiencing loss of response on upadacitinib, dose re‑escalation is one strategy discussed in the IBD community and may be considered in selected, closely monitored patients.
Decisions about escalation should be individualized, involve discussion of risks and benefits, and include plans for objective monitoring (labs, inflammatory markers, and endoscopy as indicated).
Further research—ideally prospective and comparative studies with longer follow‑up—is needed to confirm durability, safety, and which patients are most likely to benefit.
Keep In Mind
The source is an editorial summarizing a retrospective single‑center study; findings are preliminary, not randomized, and objective inflammatory/endoscopic improvements did not reach statistical significance in the reported cohort.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationWorld Journal of Gastrointestinal Pharmacology and Therapeutics
PublisherBaishideng Publishing Group Inc.
AuthorsHimanshu Agrawal, Nikhil Gupta
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 5, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Prospective Evaluation of Ustekinumab Dose Intensification in Inflammatory Bowel Diseases.
Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with...
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Predictors of ustekinumab intensified dose escalation in inflammatory bowel disease: a real-world (UST-predict) study
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For...